{"id":"rifapentine-isoniazid","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Abdominal pain"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Rifapentine and isoniazid work synergistically to inhibit the growth of Mycobacterium tuberculosis by disrupting its cell wall synthesis and fatty acid metabolism. This leads to the death of the bacteria and ultimately, the resolution of tuberculosis infection.","oneSentence":"Rifapentine inhibits the synthesis of mycolic acid in Mycobacterium tuberculosis, while isoniazid inhibits the synthesis of mycolic acid and the metabolism of fatty acids.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:52:27.040Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of tuberculosis"},{"name":"Prevention of tuberculosis in HIV-infected individuals"}]},"trialDetails":[{"nctId":"NCT06568484","phase":"PHASE2, PHASE3","title":"Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB","status":"NOT_YET_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2026-07","conditions":"Tuberculosis, Latent","enrollment":2530},{"nctId":"NCT06253715","phase":"PHASE3","title":"Shortened Regimen for Drug-susceptible TB in Children","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2025-01-15","conditions":"Tuberculosis, Tuberculosis, Pulmonary, Tuberculosis, Lymph Node","enrollment":860},{"nctId":"NCT06153069","phase":"PHASE4","title":"Asymptomatic TB With Innovative Modified Short-course Regimens","status":"RECRUITING","sponsor":"Huashan Hospital","startDate":"2025-11-21","conditions":"Tuberculosis","enrollment":426},{"nctId":"NCT07069582","phase":"PHASE1","title":"Pharmacokinetics of Antituberculosis Drugs in Breastfeeding Women","status":"NOT_YET_RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2026-04-01","conditions":"Tuberculosis Infection, Healthy Volunteer, Breastfeeding","enrollment":60},{"nctId":"NCT03089983","phase":"NA","title":"Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings","status":"COMPLETED","sponsor":"Yale University","startDate":"2017-08-21","conditions":"Opioid Dependence, Addiction, HIV/AIDS","enrollment":316},{"nctId":"NCT07124559","phase":"PHASE1, PHASE2","title":"A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIV","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-05-15","conditions":"Tuberculosis","enrollment":144},{"nctId":"NCT05411744","phase":"PHASE4","title":"One-month Latent Tuberculosis Treatment for Renal Transplant Candidates","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2022-07-01","conditions":"Latent Tuberculosis, End Stage Renal Disease, Renal Transplant Candidate for Right Kidney","enrollment":25},{"nctId":"NCT06214910","phase":"NA","title":"ThiPhiSA: New Pathways to Prevention From Community TB Screening in South Africa","status":"COMPLETED","sponsor":"University of Washington","startDate":"2024-02-20","conditions":"Tuberculosis, HIV I Infection","enrollment":301},{"nctId":"NCT07086820","phase":"NA","title":"Window Prophylaxis for Pediatric Tuberculosis Prevention Trial","status":"RECRUITING","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2025-10-27","conditions":"Tuberculosis Infection, Household Contacts, Children","enrollment":647},{"nctId":"NCT06022146","phase":"PHASE3","title":"TB YOUTH - TB sYstemic Management Using One-month, Ultra-short TPT Regimen for scHool Contacts","status":"RECRUITING","sponsor":"Huashan Hospital","startDate":"2023-09-01","conditions":"Tuberculosis, Latent Tuberculosis","enrollment":3520},{"nctId":"NCT05122767","phase":"PHASE1, PHASE2","title":"Rifapentine and Isoniazid TB Preventive Therapy (3HP) for Children Taking Dolutegravir-based Antiretroviral Treatment (DOLPHIN KIDS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Aurum Institute NPC","startDate":"2023-05-24","conditions":"Tuberculosis, HIV","enrollment":92},{"nctId":"NCT05118490","phase":"PHASE4","title":"Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Aurum Institute NPC","startDate":"2023-07-19","conditions":"HIV Seropositivity, Tuberculosis, Household Contact","enrollment":1000},{"nctId":"NCT05122026","phase":"PHASE1, PHASE2","title":"Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Aurum Institute NPC","startDate":"2024-01-17","conditions":"HIV Seropositivity, Pregnancy, Tuberculosis Infection","enrollment":252},{"nctId":"NCT05630872","phase":"PHASE2","title":"Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-02-13","conditions":"HIV-associated Tuberculosis","enrollment":30},{"nctId":"NCT02563327","phase":"PHASE3","title":"Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2016-05-30","conditions":"Tuberculosis","enrollment":53},{"nctId":"NCT04311502","phase":"PHASE2","title":"Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-11-05","conditions":"HIV, Tuberculosis","enrollment":104},{"nctId":"NCT04703075","phase":"PHASE4","title":"Ultra Curto (Ultra Short) TB Prevention Therapy","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2022-03-24","conditions":"Tuberculosis","enrollment":531},{"nctId":"NCT03730181","phase":"PHASE1, PHASE2","title":"Tuberculosis Clinical Trials Consortium Study 35","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2019-10-12","conditions":"Latent Tuberculosis","enrollment":62},{"nctId":"NCT03934931","phase":"NA","title":"Options for Delivering Isoniazid-Rifapentine (3HP) for TB Prevention (3HP Options Implementation Trial)","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2020-07-13","conditions":"Tuberculosis, Latent Tuberculosis, HIV/AIDS","enrollment":1656},{"nctId":"NCT06917495","phase":"PHASE2","title":"Short-Course Anti-tuberculosis Regimens for Mild Spinal Tuberculosis","status":"NOT_YET_RECRUITING","sponsor":"Shandong University","startDate":"2025-04-05","conditions":"Mild Spinal Tuberculosis","enrollment":300},{"nctId":"NCT06191692","phase":"PHASE3","title":"1HP Versus 3HR in the Treatment of Tuberculosis Infection in Vietnam","status":"NOT_YET_RECRUITING","sponsor":"Freundeskreis Für Internationale Tuberkulosehilfe e.V","startDate":"2025-08-01","conditions":"Tuberculosis Infection","enrollment":350},{"nctId":"NCT03785106","phase":"PHASE3","title":"Tuberculosis Preventive Therapy Among Latent Tuberculosis Infection in HIV-infected Individuals","status":"ACTIVE_NOT_RECRUITING","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2019-08-15","conditions":"HIV-infected Participants With Latent TB Infection in High TB Burden Country","enrollment":2500},{"nctId":"NCT01582711","phase":"PHASE3","title":"Study 33: Adherence to Latent Tuberculosis Infection Treatment 3HP SAT Versus 3HP DOT","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2012-09","conditions":"Latent Tuberculosis Infection","enrollment":1002},{"nctId":"NCT06874725","phase":"PHASE4","title":"Latent Tuberculosis in Type 2 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Taichung Veterans General Hospital","startDate":"2018-04-18","conditions":"Latent Tuberculosis Infection","enrollment":552},{"nctId":"NCT06281834","phase":"PHASE1","title":"Dolutegravir Pharmacokinetics During Weekly Rifapentine/Isoniazid for TB Prevention","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2024-11-15","conditions":"Pediatric HIV Infection, Latent Tuberculosis","enrollment":25},{"nctId":"NCT02410772","phase":"PHASE3","title":"TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2016-01-25","conditions":"Tuberculosis","enrollment":2516},{"nctId":"NCT03474029","phase":"PHASE2, PHASE3","title":"Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI","status":"RECRUITING","sponsor":"Centers for Disease Control and Prevention","startDate":"2019-08-01","conditions":"Latent Tuberculosis","enrollment":3400},{"nctId":"NCT04272242","phase":"PHASE2","title":"Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-02-27","conditions":"HIV Infection, LTBI","enrollment":37},{"nctId":"NCT00023452","phase":"PHASE3","title":"Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2001-06","conditions":"Tuberculosis","enrollment":8053},{"nctId":"NCT03510468","phase":"PHASE1","title":"Impact of Weekly Administration of Rifapentine and Isoniazid on Steady State Pharmacokinetics of Tenofovir Alafenamide in Healthy Volunteers (YODA)","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2018-06-12","conditions":"Healthy Volunteers","enrollment":51},{"nctId":"NCT06511180","phase":"","title":"Introduction of Dispersible 3HP Formulations for TB Preventive Treatment in Children: a Multi-country Evaluation","status":"NOT_YET_RECRUITING","sponsor":"The Aurum Institute NPC","startDate":"2024-08","conditions":"TB - Tuberculosis, Household Contact, HIV","enrollment":1200},{"nctId":"NCT04856644","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of a 4-month Daily Regimen (2HZPM/2HPM) for Treatment of Pulmonary TB","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kaohsiung Veterans General Hospital.","startDate":"2020-01-01","conditions":"Tuberculosis, Pulmonary","enrollment":333},{"nctId":"NCT05021731","phase":"PHASE4","title":"Short-course Rifamycin-based Regimens for Latent Tuberculosis in Patients With End-stage Kidney Disease","status":"NOT_YET_RECRUITING","sponsor":"Miguel Santín","startDate":"2024-04-20","conditions":"Latent Tuberculosis, Kidney Failure","enrollment":225},{"nctId":"NCT04094012","phase":"PHASE3","title":"Risk of SDRs Under 3HP and 1HP Regimen for LTBI","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2019-09-24","conditions":"Latent Tuberculosis Infection","enrollment":490},{"nctId":"NCT05330884","phase":"PHASE3","title":"BCG Revaccination in Children and Adolescents","status":"SUSPENDED","sponsor":"Tuberculosis Research Centre, India","startDate":"2024-07-15","conditions":"Tuberculosis Infection, Tuberculosis","enrollment":9200},{"nctId":"NCT05401071","phase":"PHASE2, PHASE3","title":"Optimizing(O) RIfapentine-based(RI) Regimen and shortENing(EN) the Treatment of Drug-sensitive Tuberculosis(T)","status":"RECRUITING","sponsor":"Huashan Hospital","startDate":"2023-01-13","conditions":"Tuberculosis, Pulmonary","enrollment":2442},{"nctId":"NCT03266991","phase":"PHASE4","title":"Treatment of Latent Tuberculosis in Socially Marginalised Citizens","status":"TERMINATED","sponsor":"Aarhus University Hospital","startDate":"2017-10-27","conditions":"Compliance, Patient","enrollment":22},{"nctId":"NCT03474198","phase":"PHASE2, PHASE3","title":"Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis","status":"COMPLETED","sponsor":"University College, London","startDate":"2018-03-21","conditions":"Tuberculosis, Pulmonary","enrollment":675},{"nctId":"NCT04600167","phase":"PHASE3","title":"Preventive Treatment Of Latent Tuberculosis Infection In People With Diabetes Mellitus","status":"UNKNOWN","sponsor":"Dr. Nyanda Elias Ntinginya","startDate":"2022-06-17","conditions":"Diabetes Mellitus, Tuberculosis","enrollment":3000},{"nctId":"NCT03435146","phase":"PHASE1, PHASE2","title":"Safety Tolerability DDI Short Course Treatment of LTBI Infection With High-dose Rifapentine and Isoniazid or Standard Isoniazid Preventive Therapy in HIV+ Patients (DOLPHIN & DOLPHIN TOO)","status":"COMPLETED","sponsor":"The Aurum Institute NPC","startDate":"2018-01-18","conditions":"Respiratory Tract Infections, HIV Infections","enrollment":135},{"nctId":"NCT05454345","phase":"PHASE3","title":"Sitafloxacin-containing Regimens for Shortening Tuberculosis Treatment","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2022-10-01","conditions":"Tuberculosis, Pulmonary","enrollment":620},{"nctId":"NCT05085171","phase":"PHASE3","title":"An Enhanced Package of Care to Reduce Reduce Mortality in Advanced HIV Disease","status":"RECRUITING","sponsor":"Makerere University","startDate":"2022-05-04","conditions":"The Study Will Focus on Assessing the Survival Benefit on an Enhanced Package of Care for Patients With Advanced HIV Disease","enrollment":2400},{"nctId":"NCT02771249","phase":"PHASE1","title":"Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2016-06-03","conditions":"HIV Infected Population With Latent Tuberculosis","enrollment":37},{"nctId":"NCT01404312","phase":"PHASE3","title":"Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-05-23","conditions":"Tuberculosis, HIV Infections","enrollment":3000},{"nctId":"NCT02651259","phase":"PHASE1, PHASE2","title":"Evaluating PK, Tolerability, and Safety of Rifapentine and Isoniazid in Pregnant and Postpartum Women","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-03-13","conditions":"Tuberculosis","enrollment":50},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT02641106","phase":"NA","title":"VDOT for Monitoring Adherence to LTBI Treatment","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2016-03-08","conditions":"Tuberculosis, Latent Tuberculosis Infection","enrollment":129},{"nctId":"NCT04528277","phase":"PHASE3","title":"Short Course Rifapentine and Isoniazid for the Preventive Treatment for Latent Genital Tuberculosis","status":"UNKNOWN","sponsor":"Huashan Hospital","startDate":"2020-09-01","conditions":"Infertility, Female, Recurrent Implantation Failure, Genital Tuberculoses, Female","enrollment":1050},{"nctId":"NCT02430259","phase":"PHASE3","title":"Efficacy of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention","status":"COMPLETED","sponsor":"Huashan Hospital","startDate":"2015-03","conditions":"Silicosis, Tuberculosis","enrollment":566},{"nctId":"NCT03886701","phase":"PHASE1","title":"Doravirine, Rifapentine and Isoniazid Interaction","status":"COMPLETED","sponsor":"Walter K. Kraft","startDate":"2019-04-22","conditions":"Latent Tuberculosis, Human Immunodeficiency Virus, Rifamycins Causing Adverse Effects in Therapeutic Use","enrollment":11},{"nctId":"NCT02980016","phase":"PHASE3","title":"Evaluation of the Effect of 3HP vs Periodic 3HP vs 6H in HIV-Positive Individuals","status":"COMPLETED","sponsor":"The Aurum Institute NPC","startDate":"2016-11","conditions":"Tuberculosis, HIV","enrollment":4027},{"nctId":"NCT03783728","phase":"","title":"Video Based Directly Observed Therapy for Latent TB","status":"WITHDRAWN","sponsor":"St. Louis University","startDate":"2019-06-30","conditions":"Latent Tuberculosis","enrollment":""},{"nctId":"NCT03900858","phase":"NA","title":"Short Course Rifapentine and Isoniazid for the Preventive Treatment of Tuberculosis(SCRIPT-TB)","status":"UNKNOWN","sponsor":"Huashan Hospital","startDate":"2018-12-01","conditions":"Silicosis Tuberculosis","enrollment":566},{"nctId":"NCT02735590","phase":"PHASE2, PHASE3","title":"The Correlate of Risk Targeted Intervention Study","status":"UNKNOWN","sponsor":"University of Cape Town","startDate":"2016-09-20","conditions":"Tuberculosis","enrollment":2927},{"nctId":"NCT00728507","phase":"PHASE2","title":"Rifapentine Plus Moxifloxacin for Treatment of Pulmonary Tuberculosis","status":"TERMINATED","sponsor":"Johns Hopkins University","startDate":"2009-11","conditions":"Tuberculosis","enrollment":121},{"nctId":"NCT02208427","phase":"PHASE3","title":"Toward a Safe and Reachable Preventive Therapy for LTBI: a Multicenter Randomized Controlled Study in Taiwan","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2014-08","conditions":"Latent Tuberculosis Infection","enrollment":283},{"nctId":"NCT00694629","phase":"PHASE2","title":"TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2008-12","conditions":"Pulmonary Tuberculosis","enrollment":865},{"nctId":"NCT00057122","phase":"PHASE3","title":"Tuberculosis Prevention for HIV Infected Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2002-09","conditions":"HIV Infections, Tuberculosis","enrollment":1148},{"nctId":"NCT00164450","phase":"NA","title":"TBTC Study 26 PK: Rifapentine Pharmacokinetics in Children During Treatment of Latent TB Infection","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2005-09","conditions":"Tuberculosis","enrollment":230},{"nctId":"NCT00023387","phase":"NA","title":"TBTC Study 25PK: Intensive Pharmacokinetic Study of Three Doses of Rifapentine and 25-Desacetyl Rifapentine","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2000-03","conditions":"Tuberculosis","enrollment":36},{"nctId":"NCT00023335","phase":"PHASE3","title":"TBTC Study 22: Efficacy of Once-Weekly Rifapentine and Isoniazid in Treatment of Tuberculosis","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"1995-04","conditions":"Pulmonary Tuberculosis","enrollment":1000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Priftin (rifapentine)"],"phase":"phase_3","status":"active","brandName":"rifapentine + isoniazid","genericName":"rifapentine + isoniazid","companyName":"The Aurum Institute NPC","companyId":"the-aurum-institute-npc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rifapentine inhibits the synthesis of mycolic acid in Mycobacterium tuberculosis, while isoniazid inhibits the synthesis of mycolic acid and the metabolism of fatty acids. Used for Treatment of tuberculosis, Prevention of tuberculosis in HIV-infected individuals.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}